Obstructive Sleep Apnea News and Research

RSS

Obstructive sleep apnea (OSA) is a major heath problem. In the United States, at least 17 million people have moderate to severe OSA, which is characterized by heavy snoring, airway blockage and frequent awakenings during sleep.

OSA underdiagnosed among primary care diabetes patients

Obstructive sleep apnea is commonly underdiagnosed in patients with Type 2 diabetes in primary care, suggest study findings.

22 Jun 2012

SomnoMed and Sleep HealthCenters partner to create National Center for Integrated Dental Sleep Health

SomnoMed and Sleep HealthCenters are pleased to announce a partnership to create the National Center for Integrated Dental Sleep Health (NCIDSH) program.

19 Jun 2012

OSA independently linked with DPN in patients with type 2 diabetes mellitus

Obstructive sleep apnea (OSA) is independently associated with diabetic peripheral neuropathy (DPN) in patients with type 2 diabetes mellitus (T2DM), according to a new study from researchers in the UK. The severity of DPN is also correlated with the degree of OSA and the severity of nocturnal hypoxemia.

15 Jun 2012

Viewpoints: Puzzling slowdown in health spending; Court decision could help end businesses' fears about health law

Economists will debate the causes of the great slowdown in health-care spending that's now underway for a long time to come. ... And last year, preliminary government estimates released Tuesday showed, health care spending once again grew at just a 3.9 percent rate.

14 Jun 2012

Another benefit of CPAP therapy for men with OSA

Men who suffer from obstructive sleep apnea (OSA) are seeing another potential benefit from continuous positive airway pressure therapy, or CPAP: improved sexual function and satisfaction in non-diabetic men under age 60.

13 Jun 2012

Researchers encourage PCPs to screen for OSA in patients with Type 2 diabetes

Researchers in New Jersey are encouraging primary care physicians to screen for obstructive sleep apnea (OSA) in patients with Type 2 diabetes. They found that in a small sample of clinic patients, the risk for sleep apnea was high among diabetics compared with non-diabetics, and that sleep apnea appeared to be associated with carbohydrate craving.

13 Jun 2012

Depression, obesity two main culprits of excessive daytime sleepiness

Wake up, America, and lose some weight - it's keeping you tired and prone to accidents. Three studies being presented today at sleep 2012 conclude that obesity and depression are the two main culprits making us excessively sleepy while awake.

13 Jun 2012

OSA negatively impacts youths’ ability to regulate life skills

The number of children with obstructive sleep apnea (OSA) declines as they enter adolescence, but the teen years can be a devastating trial of behavior and learning problems for kids with persistent OSA, new research shows.

12 Jun 2012

Positive airway pressure reduces depressive symptoms in patients with OSA

Patients seen at the Cleveland Clinic Sleep Disorders Center who used positive airway pressure (PAP) to treat their obstructive sleep apnea (OSA) had improvements in their depressive symptoms, even if they followed the prescribed PAP regimen only partly, a new study reports.

12 Jun 2012

Researcher uncovers link between pro athlete's longevity and sleepiness

Coaches, owners and fantasy-league traders take note: Sleep researcher W. Christopher Winter, MD, has uncovered a link between a pro athlete's longevity and the degree of sleepiness experienced in the daytime.

12 Jun 2012

Short sleep periods increase risk of stroke in normal-weight adults

Habitually sleeping less than six hours a night significantly increases the risk of stroke symptoms among middle-age to older adults who are of normal weight and at low risk for obstructive sleep apnea (OSA), according to a study of 5,666 people followed for up to three years.

11 Jun 2012

Oxidative stress burdens obstructive sleep apnea patients

Obstructive sleep apnea may be associated with increased oxidative burden, say researchers.

8 Jun 2012

Mylan, Teva resolve generic Provigil litigation

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has resolved all disputes with Teva Pharmaceuticals USA, Inc. stemming from litigation brought by Mylan in federal court in the District of Columbia against the U.S. Food and Drug Administration (FDA) concerning Mylan's abbreviated new drug application (ANDA) for Modafinil Tablets, 100 mg and 200 mg.

8 Jun 2012

Severity of nocturnal hypoxemia and SDB independently predict both T2DM and HbA1c levels

The severity of sleep disordered breathing and nocturnal hypoxemia independently predict both glycosylated hemoglobin (HbA1c) levels and type 2 diabetes mellitus (T2DM), according to a new study.

24 May 2012

Studies examine effectiveness of CPAP in reducing risk of cardiovascular outcomes linked with OSA

Two studies that included adults with obstructive sleep apnea examined the effectiveness of reducing the risk of cardiovascular outcomes, including high blood pressure, by treatment with continuous positive airway pressure (CPAP), according to the articles in the May 23/30 issue of JAMA.

23 May 2012

Primary care-based management can reduce burden of OSA

Patients with moderate-to-severe obstructive sleep apnea (OSA) can be successfully managed in a primary care setting by appropriately trained primary care physicians (PCPs) and community-based nurses, according to Australian researchers.

21 May 2012

Treatment of OSA in children can reverse neuronal brain injury

Treatment of obstructive sleep apnea (OSA) in children normalizes disturbances in the neuronal network responsible for attention and executive function, according to a new study.

21 May 2012

Teva, Mylan settle patent infringement litigation for Nuvigil

Teva Pharmaceutical Industries Ltd., one of the world's largest producers of pharmaceuticals, announces that it has settled patent infringement litigation regarding U.S. Patent Number 7,132,570 (the "'570 patent") with respect to Mylan Inc.'s ANDA for Teva's wakefulness product NUVIGIL (armodafinil) tablets.

30 Apr 2012

FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S.

30 Apr 2012

Enrollment complete for In-tunnel SeptRx European PFO Trial in Europe

SeptRx, an emerging medical device company that has developed the SeptRx Intrapocket PFO Occluder (IPO), reported today that it has completed enrollment for its "InterSEPT" (In-tunnel SeptRx European PFO Trial) clinical trial in Europe, and has entered into a partnership with CoRRect Medical GmbH for commercial distribution in Germany and Switzerland of the SeptRx IPO.

23 Apr 2012